Gilead Sciences Inc (GIS.HM)

92.28

+6.17

+(7.17%)

As of 5:25:14 PM GMT+2. Market Open.

Trump expected to sign order to slash US drug prices

President Trump is expected to sign an executive order intended to cut US prescription drug prices in order to match drug prices overseas. Yahoo Finance senior health reporter Anjalee Khemlani outlines the many steps and government agencies involved in investigating and carrying out this act. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Yahoo Finance Video 4 hours ago

NONOF

NVO

GILD
US-China trade truce, April CPI, drug prices: 3 Things

US stock futures (ES=F, NQ=F, YM=F) are surging Monday morning after US and China officials agreed to significant cuts to each country's respective tariff rates in a 90-day cool-off period. April's Consumer Price Index (CPI) is due out tomorrow, reporting month-over-month trends in US inflation rates. President Trump vows to cut prescription drug prices by as much as 80%. In turn, pharmaceutical stocks are seeing across the board pullbacks in pre-market trading. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Yahoo Finance Video 5 hours ago

ES=F

PFE

JNJ
Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know

A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains.

StockStory 51 minutes ago

GILD

TMO

MRNA
The Zacks Analyst Blog Highlights Disney, Gilead Sciences, Eaton and Maui Land & Pineapple

Disney, Gilead Sciences, Eaton and Maui Land & Pineapple are included in this Analyst Blog.

Zacks 4 hours ago

DIS

GILD

ETN
GILD Q1 Earnings Call: HIV Growth and Pipeline Momentum Offset Revenue Miss

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue guidance of $28.4 billion at the midpoint came in 1.1% below analysts’ estimates. Its non-GAAP profit of $1.81 per share was 2.1% above analysts’ consensus estimates.

StockStory 8 hours ago

GILD
Is Gilead Sciences (GILD) Among the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies?

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other best stocks to buy according to Jim Simons’ Renaissance Technologies. Even after his passing in 2024, billionaire investor and […]

Insider Monkey 22 hours ago

GILD
2 High-Yield Dividend Stocks to Buy in May and Hold Forever

AbbVie has a rare dividend track record and impressive innovative abilities. Gilead is a leader in its core market and increasingly growing a presence in others. When investing in dividend stocks, paying attention to the right things is essential.

Motley Fool 2 days ago

ABBV

GILD
Top Analyst Reports for Walt Disney, Gilead Sciences & Eaton

Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Co. (DIS), Gilead Sciences, Inc. (GILD) and Eaton Corp. plc (ETN), as well as a micro-cap stock Maui Land & Pineapple Co., Inc. (MLP).

Zacks 2 days ago

DIS

ETN

GILD
3 Value Stocks with Mounting Challenges

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.

StockStory 3 days ago

AYI

GILD
Gilead reports final outcomes from trial of bulevirtide for chronic HDV

The trial is aimed at assessing long-term efficacy as well as safety of the therapy in 150 chronic HDV patients.

Clinical Trials Arena 4 days ago

GILD
How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock

Gilead Sciences (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the U.S. and internationally. The 52-week range of Gilead Sciences stock price was $62.07 to ...

Benzinga 4 days ago

GILD
Gilead to Invest $11 Billion to Bolster Domestic Operations

Gilead Sciences said Wednesday it will invest $11 billion in U.S. research and manufacturing in the coming years, joining other drugmakers that have promised to bolster domestic capabilities as they brace for tariffs from the Trump administration. Johnson & Johnson, Merck and Novartis are among the companies that have made investment pledges for the coming years, with an aggregate total of more than $200 billion. The administration is currently conducting an investigation into potential tariffs on the pharmaceutical industry.

The Wall Street Journal 4 days ago

GILD
Gilead Sciences to invest $11 billion in U.S. R&D and manufacturing

Gilead Sciences (NASDAQ:GILD), a leading biopharmaceutical company, has today outlined plans to create $43 billion in value for the U.S. economy over the next five years through direct capital investment and job creation. The latest initiative will further grow the company’s presence in the U.S., which currently hosts Gilead’s largest research, development, and manufacturing footprint globally.

Investing.com 4 days ago

GILD
Gilead boosts planned US investments by $11 billion amid tariff threat

The new investments, unveiled on Wednesday, will supplement an already planned spending of $21 billion to boost U.S. manufacturing and research and development through 2030, the drugmaker said. These investments will be used for new technology, building three new facilities and upgrading three existing sites, it said. Major U.S. drugmakers, including Eli Lilly, Johnson & Johnson, Merck and Bristol Myers Squibb, have also recently announced additional investments to boost domestic production amid the tariff threat.

Reuters 5 days ago

GILD
Gilead Sciences (NasdaqGS:GILD) Presents Promising Data On Livdelzi And Bulevirtide At EASL 2025

Gilead Sciences (NasdaqGS:GILD) announced positive data regarding Livdelzi for PBC and bulevirtide for chronic HDV, underscoring progress in liver disease treatment. During the last quarter, the company also reported Q1 financial results, announced positive outcomes for Trodelvy in cancer treatment, and shared updates on strategic partnerships, all highlighting its ongoing innovation. Despite these developments, Gilead's share price saw a minor 1.78% decline, in line with a flat market...

Simply Wall St. 5 days ago

GILD
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

FOSTER CITY, Calif., May 07, 2025--Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with chronic hepatitis delta virus (HDV) treated with the first-in-class entry inhibitor bulevirtide at either a 2 mg or 10 mg dose maintained virologic suppression for almost two years after stopping treatment after achieving undetectable HDV RNA at end of treatment (EOT). In participants who sustained undet

Business Wire 5 days ago

GILD
Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025

FOSTER CITY, Calif., May 07, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated for the treatment of primary biliary cholangitis (PBC) and also provides sustained biochemical response in adults with PBC regardless of prior treatment history. Another analysis provides evidence supporting that Livdelzi delivered clinically and stat

Business Wire 5 days ago

GILD
Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions"

NORTHAMPTON, MA / ACCESS Newswire / May 6, 2025 / At Gilead, we set and achieve bold ambitions in our fight against the world's most devastating diseases. In this installment of The Centrifuge Sessions, See Phan, Vice President, Oncology Clinical ...

ACCESS Newswire 6 days ago

GILD
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 7 days ago

GILD
1 Profitable Stock on Our Watchlist and 2 to Turn Down

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

StockStory 7 days ago

GILD

VEEV

Performance Overview

Return	GIS.HM	S&P 500 (^GSPC)
YTD	+3.42%	-0.88%
1-Year	+59.91%	+11.63%
3-Year	+81.88%	+48.35%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TARIFFS LATEST

Gilead Sciences Inc (GIS.HM)

Trump expected to sign order to slash US drug prices

US-China trade truce, April CPI, drug prices: 3 Things

Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know

The Zacks Analyst Blog Highlights Disney, Gilead Sciences, Eaton and Maui Land & Pineapple

GILD Q1 Earnings Call: HIV Growth and Pipeline Momentum Offset Revenue Miss

Is Gilead Sciences (GILD) Among the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies?

2 High-Yield Dividend Stocks to Buy in May and Hold Forever

Top Analyst Reports for Walt Disney, Gilead Sciences & Eaton

3 Value Stocks with Mounting Challenges

Gilead reports final outcomes from trial of bulevirtide for chronic HDV

How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock

Gilead to Invest $11 Billion to Bolster Domestic Operations

Gilead Sciences to invest $11 billion in U.S. R&D and manufacturing

Gilead boosts planned US investments by $11 billion amid tariff threat

Gilead Sciences (NasdaqGS:GILD) Presents Promising Data On Livdelzi And Bulevirtide At EASL 2025

Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025

Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions"

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

1 Profitable Stock on Our Watchlist and 2 to Turn Down

Performance Overview